Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

      This paper is only available as a PDF. To read, Please Download here.


      Psoriasis is a chronic, inflammatory, multisystem disease which affects up to 3.2% of the U.S population. This guideline addresses important clinical questions that arise in psoriasis management and care and provides recommendations based on the available evidence. The treatment of psoriasis with topical agents and with alternative medicine (AM) will be reviewed, emphasizing treatment recommendations and the role of dermatologists in monitoring and educating patients regarding benefits as well as risks that may be associated. This guideline will also address the severity assessment methods of psoriasis in adults.



      AAD ( American Academy of Dermatology), AM ( Alternative medicine), AV ( Aloe Vera), BSA ( body surface area), CYA ( Cyclosporine), DLQI ( Dermatology Life Quality Index), EPA ( Eicosapentaenoic acid), FDA ( the Food and Drug Administration), GFD ( Gluten-free diet), HM ( Herbal medicine), HPA ( hypothalamic-pituitary-adrenal), LCD ( Liquor carbonis detergens), NB-UVB ( narrow band ultraviolet B), NPF ( National Psoriasis Foundation), NAPSI ( Nail Psoriasis Severity Index), PASI ( Psoriasis Area Severity Index), PCB ( Polychlorinated biphenyls), PGA ( Physician's Global Assessment), PsA ( Psoriatic arthritis), PSI ( Psoriasis symptom inventory), QOL ( Quality of life), RCT ( Randomized controlled trial), SORT ( Strength of Recommendation Taxonomy), UVA ( ultraviolet A), UVB ( ultraviolet B), WG ( Work group)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect